Immunitybio Inc (IBRX) stock has gained 168.66% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives IBRX stock a score of 34 out of a possible 100.
That rank is mainly influenced by a short-term technical score of 21. IBRX's rank also includes a long-term technical score of 21. The fundamental score for IBRX is 59. In addition to the average rating from Wall Street analysts, IBRX stock has a mean target price of 25. This means analysts expect the stock to increase 59.34% over the next 12 months.
What's Happening with IBRX Stock Today
Immunitybio Inc (IBRX) stock is lower by -10.42% while the S&P 500 has fallen -0.3% as of 11:45 AM on Monday, Jun 7. IBRX has fallen -$1.82 from the previous closing price of $17.51 on volume of 971,986 shares. Over the past year the S&P 500 has risen 30.47% while IBRX has gained 168.66%. IBRX lost -$0.91 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Immunitybio Inc (IBRX) Stock.
